N., Mooney, L., Yeo, L., Kirwan, B
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
Retatrutide Pharmacokinetics Retatrutide Half-Life: What the Phase 2 Data Actually Shows Retatrutide has a half-life of approximately 6 days, according to the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023)
Discrepancy between the actions of glucagon-like Peptide-1 receptor ligands in the Protection of the heart against Ischemia Reperfusion Injury
